Celltrion Offers Real-World Data On Rituximab
Presents New Data On Truxima Biosimilar In Diffuse Large B-cell Lymphoma Patients
South Korea’s Celltrion has announced positive results from its recent study on the real-world clinical effectiveness and safety of its Truxima (rituximab) or CT-P10 biosimilar in patients with diffuse large B-cell lymphoma. The company presented its findings at the recently held European Hematology Association 2021 virtual congress.
